
|Videos|July 20, 2022
Urology Times 50 Innovations Series: LHRH analogues in prostate cancer
Author(s)Urology Times staff
“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5
























































